Quality by design aproaches to clarification in monoclonal antibody processing
WEBINAR
In this webinar, you will learn about:
- Quality by design
- Process characterization & scale down, risk assessment, establishing design space and control strategy for clarification for monoclonal antibody to achieve high process efficiency and purity
Quality by design (QbD) is a modern, scientific approach promoted by health authorities to improve the quality of therapeutic products which requires deep understanding of both product and process.
This seminar will provide an overview on principles of QbD for a harvest clarification process in monoclonal antibody processing; where the product of interest is extracellular and impurities are removed in the filtrate post-clarification. It will include methods for optimizing the clarification unit operation using QbD principles, ensuring better process efficiency, and product quality.
Speaker List

Subhasis Banerjee, Ph.D.
Merck
Principal Process Consultant, APAC
Subhasis Banerjee is the Principal Process Consultant in the Technical & Scientific Solutions group of Process Solutions at our company based out of Bangalore, India. Subhasis supports technical consultation on Process Development , Scaleup and troubleshooting for downstream processing for the APAC region, working for the last 18 years in our company. He is a Ph.D. in Biochemistry with a post-doctoral experience from The Ohio State University, Columbus, Ohio, USA. Dr. Banerjee has several publications in international peer reviewed journals and presentations in several national and International Conferences.

Kevin Yeop
Merck
Process Development Scientist, DSP, MSAT, Korea.
Kevin Yeop holds a Master’s degree in Chemistry and Biotechnology from Ajou University. At our company, he is responsible for downstream process development, specializing in TFF and Vaccine and Viral Gene Therapy (VVT) as a global focal point and Korea representative in DSP MSAT. He supports technical partnerships across drug development phases. Previously, he has spent over 12 years at our company, SK Bioscience, Osstem Implant BPD, and CJ Bio Institute, focusing on process development. His expertise spans purification, analytical method development, and cell culture optimization, including scale-up. He notably managed CDMO projects for COVID-19 vaccines and led process development for recombinant proteins, covering DS, DP, and analytical method establishment for novel biologics.
Pharma and biopharma manufacturing
- Monoclonal antibody manufacturing
Duration:1h
Language:English
Session 1:presented February 24, 2026
To continue reading please sign in or create an account.
Don't Have An Account?